Cell-permeable bone morphogenetic protein 2 facilitates bone regeneration by promoting osteogenesis.

Area of Science:

• Biomaterials Science
• Regenerative Medicine
• Orthopedic Surgery

Background:

• Bone Morphogenetic Protein 2 (BMP2) is an FDA-approved osteoinductive growth factor crucial for bone regeneration.
• Clinical use of BMP2 is limited by poor cell permeability and short circulation half-life.
• A modified BMP2, CP-BMP2, was developed to overcome these limitations.

Purpose of the Study:

• To develop and evaluate a modified BMP2 (CP-BMP2) with enhanced cell permeability and bioavailability for bone regeneration.
• To assess the efficacy of CP-BMP2 in promoting bone formation in preclinical animal models.

Main Methods:

• CP-BMP2 was engineered with an advanced macromolecular transduction domain (aMTD) for improved cell membrane transfer and a solubilization domain.
• Effectiveness was evaluated in mice and rabbits with calvarial defects and in horses with hind limb bone injuries.
• Subcutaneous injections of CP-BMP2 and rhBMP2 were administered over 8 weeks, with bone formation assessed via Micro-CT and other methods.

Main Results:

• CP-BMP2 significantly increased bone formation by 65% in mice compared to vehicle and rhBMP2.
• Rabbits treated with CP-BMP2 showed faster bone regeneration, with central filling patterns.
• Horses treated with CP-BMP2 demonstrated an 85% higher bone regeneration rate in hind limb injuries compared to controls.

Conclusions:

• CP-BMP2 exhibits superior cell permeability, solubility, and bioavailability compared to traditional rhBMP2.
• CP-BMP2 effectively promotes significant bone regeneration in multiple animal models.
• CP-BMP2 demonstrates therapeutic potential as a safe and effective novel osteogenic agent without adverse effects.